Bexarotene (CAS 153559-49-0) – Anticancer API

Bexarotene (CAS 153559-49-0) is a high-potency selective retinoid X receptor (RXR) agonist anticancer API, with a targeted mechanism that modulates gene expression to inhibit cancer cell proliferation and induce differentiation. Its unique molecular structure binds specifically to RXR subtypes, activating downstream signaling pathways to suppress tumor growth without significant systemic toxicity. Produced under strict GMP-certified processes, it ensures ultra-high purity, consistent bioactivity, and compliance with global oncology drug quality standards.

This premium API is a core raw material for pharmaceutical manufacturers developing targeted skin cancer therapies. It is widely applied in formulating medications for cutaneous T-cell lymphoma (CTCL), especially for patients with refractory or recurrent disease. With proven clinical efficacy in improving patient response rates and reducing tumor burden, it addresses the critical demand for specialized anticancer treatments. For pharmaceutical R&D teams and production enterprises, it provides a trusted solution to advance precision oncology care for skin malignancies.